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Abstract 
The aim of the present study was to prepare niosome formulations for the simultaneous 
encapsulation, dual drug therapy, of two anticancer drugs by the ecological probe 
sonication method. Poloxamer and sorbitan monostearate were used as surface active 
agents in niosomes, and the water soluble doxorubicin and poorly-water soluble paclitaxel 
were used as anticancer drugs. Thorough physicochemical analysis were performed for the 
niosomes, and their cytotoxicity and activity were evaluated on MCF-7 and PC3-MM2 
cancer cell lines. Prepared niosomes were small in size with sizes ranging from 137 nm to 
893 nm, and entrapment efficiencies were high, ranging from 91.24% to 99.99%. During 
the four weeks stability testing, the particle size remained stable. The niosomal 
formulations showed in vitro sustained drug release profiles for doxorubicin and clearly 
increased the dissolution rate of poorly water soluble paclitaxel. The incorporation of both 
the drugs into niosomes improved cell penetration and antiproliferative activity of the drugs 
PC3-MM2 cell lines. As a conclusion, doxorubicin and paclitaxel loaded niosome 
formulations resulted in relatively stable, small sized niosomes with improved drug release 
profiles, low toxicity, better cell penetration and antiproliferative activity. The niosomes 
showed synergistic effect due to the presence of both drugs, which can overcome multidrug 
resistance.  
Keywords: antiproliferative activity, cell penetration, doxorubicin, dual drug therapy, 
paclitaxel, niosomes    
1. Introduction 
Cancer is one of the causative factors of death around the world in many countries 
(Yingchoncharoen et al., 2016), and chemotherapy is among the approaches, which is 
effective against multiple cancers (Tahir et al., 2017). However, the chemotherapeutics 
have toxic adverse effects on healthy living cells regardless of selectivity (Zheng et al., 
2015). Due to high toxicity and shorter half-life, the use of chemotherapeutics is limited to 
avoid toxicity. Accordingly, in order to avoid the hazardous adverse effects, the challenge 
is that chemotherapeutical agents are needed to be delivered only to the cancer cells with 
minimum delivery to normal cells (Yingchoncharoen et al., 2016; Tahir et al., 2017).  
Different nanosized systems are the carrier of choice for the efficient loading of the drugs 
(hydrophilic or hydrophobic) in order to reach site specificity, prolonged circulation time 
in body, and lower toxicity (Sharma et al., 2015). Niosomes, vesicular structures composed 
of non-ionic surfactants, are capable of encapsulating both hydrophobic as well as 
hydrophilic drugs (Sharma et al., 2016). Niosomes have advantages over liposomes, like 
higher stability and entrapment efficiency, biocompatibility, non-immunogenicity and 
lower costs (Manconi et al., 2002; Tavano et al., 2014). A number of non-ionic surfactants, 
like alkyl ethers, alkyl esters, polysorbates, poloxamers and alkyl amides, have been used 
to produce niosomes (Di Marzio et al., 2011; Escudero et al., 2014; Moghassemi et al., 
2014).  
Poloxamers are promising non-ionic polymeric surfactants, which have been used for 
niosome production and delivery of anticancer drugs for the treatment of multidrug 
resistant cancers. Pluronic L121 is one of the poloxamers used for the encapsulation of 
cytotoxic drugs, and it is also P-glycoprotein (P-gp) inhibitor (Yang et al., 2007b). In most 
of the niosomal studies, only a single surfactant has been used (Di Marzio et al., 2011; 
Escudero et al., 2014; Moghassemi et al., 2014). However, when two or more non-ionic 
amphiphiles are used, more stable, small in size, monodispersed niosomes with better drug 
release profiles can be reached (Khan et al., 2016).  
Niosomes are produced by different methods, the most adopted being reverse phase 
evaporation, thin film hydration, ether injection and shaking methods (Kanaani et al., 2017; 
Ravalika and Sailaja, 2017). These methods are time consuming and expensive, they use 
organic solvents, and after the production, solvent removal is laborous. Probe sonication 
method has been developed to overcome these problems (Dufes et al., 2000). It is a green 
technique with low energy consumption and without the addition of any organic solvents. 
In this method, only aqueous drug phase is mixed with surfactants, cholesterol and other 
bilayer membrane additives (Khan et al., 2017).  
Doxorubicin (DOX) and paclitaxel (PXT), chemotherapeutic agents belonging to 
anthracycline and taxanes classes of cytotoxic drugs, respectively, are effective against 
number of cancers, including breast and prostatic cancers (Kim et al., 2015; Pawar et al., 
2016). DOX is hydrophilic in nature, but, PXT is hydrophobic, which limits its 
bioavailability (Alemi et al., 2018; Behnam et al., 2018). Besides, the delivery of these 
cytotoxic drugs is challenging due to their highly toxic adverse effects and drug resistance 
(Liu et al., 2017; Teixeira et al., 2017; Sayed et al., 2018). However, it has been shown that 
the combination of DOX and PXT  have a great attraction due to synergistic effect with 
reduced systematic toxicity and higher antitumor efficacy (Devita et al., 1975; Chabner and 
Roberts, 2005; Al-Lazikani et al., 2012; Ag Seleci et al., 2017; Alemi et al., 2018, Yang et 
al., 2019). 
In the present study, co-delivery formulation of two anticancer drugs, DOX and PTX were 
prepared by an environmental friendly probe sonication method. The aims of the dual drug 
therapy were synergistic effects with lower toxicity levels and higher antitumor efficacy. 
Niosomes containing only a single drug, as well as both the drugs, were formulated. 
Pluronic L121 and Span 60 surfactants were utilized for production of niosomes. 
Performance of niosomal formulations was confirmed by thorough physicochemical 
analysis and efficiency of the formulations were confirmed in vitro in different cancer cell 
lines. 
2. Materials and methods 
2.1 Materials 
Doxorubicin hydrochloride (Fluorochem, UK) and paclitaxel (Fluorochem, UK) were 
studied chemotherapeutic drug substances. Sorbitan Monostearate (Span 60, Sigma-
Aldrich, USA) and Polyethylene oxide - Polypropylene oxide - Polyethylene oxide (PEO-
PPO-PEO) block copolymer (Pluronic L121, Mn 4400, Sigma-Aldrich, USA) were used 
as bilayer membrane formers in niosomes. Cholesterol (Sigma-Aldrich, USA) was used as 
membrane stabilizer and dicetylphosphate (DCP, Sigma-Aldrich, USA) as charge 
imparting agent. Hank’s Balanced Salt Solution (HBSS), and Dulbecco’s Modified Eagle’s 
Medium (DMEM) were purchased from HyClone (USA). Tween 80 was used as a 
solubilizing agent in dissolution testing (Sigma-Aldrich, USA). Water used in all the tests 
was Milli-Q water (Millipore, Merckmillipore, USA). 
2.2 Methods 
2.2.1 Preparation of niosomes 
The niosomes were prepared by probe sonication method (Khan et al., 2019). First, the 
drugs, doxorubicin-HCl (DOX) and paclitaxel (PXT), individually or as a combination, 
were mixed with 15 mL of water with the aid of magnetic stirrer, after which cholesterol, 
Span 60, Pluronic L121, and dicetylphosphate (DCP) were added. The compositions of 
different studied formulations are indicated in Table 1. The mixtures were then subjected 
to probe sonication (Vibra Cell, Sonics & Materials, Inc., USA) for 5 min time at 57°C 
probe temperature in a pulsatile manner (50 sec sonication with 10 sec pause) at an 
amplitude of 30%. After probe sonication, niosome formulations were collected and stored 
at 4°C for further characterization and cell line studies. 
  
Table 1: Compositions of studied niosome formulations. 
Formulations 
Span 60 
(mg) 
Pluronic 
L121 (mg) 
Cholesterol 
(mg) 
DCP 
(mg) 
DOX 
(mg) 
PXT 
(mg) 
Water 
(mL) 
D1 43 290 77.3 1 2 - 15 
D2 43 290 77.3 2 2 - 15 
D3 43 290 77.3 0 2 - 15 
D4 43 246 77.3 1 2 - 15 
D5 43 334 77.3 1 2 - 15 
P1 43 290 77.3 1 - 2 15 
P2 43 290 77.3 2 - 2 15 
P3 43 290 77.3 0 - 2 15 
P4 43 246 77.3 1 - 2 15 
P5 43 334 77.3 1 - 2 15 
DP1 43 290 77.3 1 2 2 15 
DP2 43 290 77.3 2 2 2 15 
DP3 43 290 77.3 0 2 2 15 
DP4 43 246 77.3 1 2 2 15 
DP5 43 334 77.3 1 2 2 15 
E1 43 290 77.3 1 - - 15 
E2 43 290 77.3 2 - - 15 
E3 43 290 77.3 0 - - 15 
E4 43 246 77.3 1 - - 15 
E5 43 334 77.3 1 - - 15 
 
2.2.2 Particle size, size deviation and zeta-potential 
The diameter of the niosomes (z-average) and polydispersity index (PDI), based on 
dynamic light scattering (DLS) technique, as well as zeta-potential, were measured by 
using Zeta-sizer Nano ZS (Malvern Instruments Ltd., USA). The niosomal dispersions 
were diluted with water before the measurement to avoid multi scattering phenomenon. All 
the measurements were performed in triplicate. 
2.2.3 Drug entrapment efficiency  
For drug entrapment efficiency determinations, the formulations were ultracentrifuged at 
14,500 rpm for 45 min time (Sigma Laborzentrifugen, D-37520, Germany). The 
supernatant was collected, the pellet at the bottom of the centrifuge tube was washed twice 
with water, water was collected, and centrifugation was repeated. Drug concentration in the 
aqueous portion of supernatants was determined. For PXT determination, high performance 
liquid chromatography (HPLC, Agilent 1260, Agilent Technologies, USA), and for DOX, 
spectrophotometric analysis (Varioskan Flesh, Thermo Fisher Scientific Inc., USA), were 
used. The percentage entrapment (EE%) of drugs were calculated according to the 
following equation (Equation 1) (Li et al., 2016; Maestrelli et al., 2017):  
EE% = [(Qt - Qr)/Qt] x 100,     (1) 
where Qt is the amount of drug initially used for the preparation of niosomes and Qr is the 
amount of drug present in supernatant after centrifugation.  
2.2.4 Transmission electron microscopy 
The morphology of the niosomes was investigated by the transmission electron microscopy 
(TEM, Jeol JEM-1400, Jeol Ltd, Japan). For TEM analysis, small amount of niosomal 
dispersions were inserted on a carbon coated 200-mesh sized copper grid. The mesh was 
positioned horizontally for one minute, superfluous was removed with the aid of filter paper 
and one drop of 2% uranyl acetate was placed on the sample for staining (Somjid et al., 
2018). 
2.2.5 Attenuated total reflectance - fourier transform infrared (ATR-FTIR) spectroscopy 
The possible interactions between the drug, the non-ionic surfactants and other membrane 
additives were studied by attenuated total reflectance - fourier transform infrared (ATR-
FTIR) spectroscopy. The ATR-FTIR spectra of all the individual components, their 
physical mixtures and niosome formulations containing DOX, PXT and DOX+PXT were 
measured. For ATR-FTIR analysis, the niosome dispersions were centrifuged, and the dried 
pellet was analyzed. The spectra were recorded by using FTIR spectrophotometer (Bruker 
Optics, Germany) with an additional horizontal accessory of ATR (MIRacle, Pike 
Technology, Inc., Germany). The spectra were recorded at an ambient temperature between 
wavenumbers of 400-4500 cm-1 with 4 cm-1 resolution by using OPUS 5.5 software. 
2.2.6 Thermal analysis 
The physical states of the DOX and PXT in the formulations were estimated by using 
differential scanning calorimetry (DSC 823e, Mettler Toledo, USA). Pure DOX, PXT, 
individual niosome constituents, their physical mixtures, and formulations containing 
DOX, PXT and DOX+PXT were accurately weighed (3-5 mg) in closed aluminum pan. 
For DSC analysis, the niosome dispersions were centrifuged, and the dried pellet was 
analyzed. The thermal scanning was carried out from 25°C to 260°C with a heating rate of 
5°C/min. The analysis were conducted under the nitrogen gas flow (50 ml/min).  
2.2.7 Stability studies 
Four weeks stability study of niosome formulations was performed by storing the niosomal 
dispersions in sealed 20 mL glass vials at 4°C in refrigerator. The size, PDI and zeta-
potential of the stored formulations were assessed at predefined time intervals (fresh 
samples, 1, 2, 3 and 4 weeks after production). 
2.2.8 Dissolution studies 
The dissolution studies were carried out in a glass vessel containing magnetic stirrer. HBSS 
with HEPES (Hanks' balanced salt solution with N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid) buffer pH 7.4 solution with 4% Tween 80 was used as dissolution 
medium. For the dissolution study, the aqueous dispersions of the formulations (2 mL) were 
put into the dissolution vessel containing dissolution medium. The study was conducted at 
37°C, the amount of the medium was 250 mL, and stirring speed was 100 rpm. The aliquots 
were sampled at predefined time intervals (0, 15 min, 30 min, 45 min, 60 min, 1.5 h, 2 h, 3 
h, 4 h, 6 h, 8 h, 12 h, and 24 h), and replaced with the same volume of fresh buffer. Samples 
withdrawn from the dissolution media were analyzed as such using a spectrophotometer 
with a wavelength of 480 nm for DOX, and HPLC for PXT.  
Dissolution studies for the pure drugs in powdered form were carried out using the same 
protocol. 
2.2.9 High performance liquid chromatography (HPLC) 
In the HPLC method, the column used for the PXT detection was C18 (4.6 × 150 mm × 5 
mm, Supelco Discovery C18, Phenomenex, USA), and the mobile phase used consist of 
water and acetonitrile (53:47, v/v). The flow rate was 1.0 mL/min, the temperature of 
column was 25°C, and the wavelength used for the drug detection was 227 nm. The injected 
volume of the drug solution was 20 µL. 
2.2.10 Cell culturing 
The MCF-7 breast cancer cells and PC3-MM2 human prostate cancer cells were grown in 
75 cm2 culture flasks (Corning Inc. Life Sciences, USA). The incubation was performed in 
5% CO2 in a gas incubator (Heraeus Instruments GmbH, Germany) at 37°C with 95% 
relative humidity. MCF-7 and PC3-MM2 cells were cultured in DMEM culture medium. 
The medium was supplemented with 1% non-essential amino acids (NEAA), 10% (v/v) 
fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin (PEST). Cells 
were thawed from the frozen stock and sub cultured at 80% confluency. 
2.2.11 Cytotoxicity studies  
The in vitro cytotoxicity of the niosomes was studied for the evaluation of the safety of the 
formulations. The viability of MCF-7 and PC3-MM2 cells was determined using an ATP-
based cell viability kit.  
Briefly, the cells were seeded in 96-well plates at a concentration of 2 × 105 cells/mL (100 
μL) and incubated overnight for the attachment. The niosomes were prepared in the 
medium with the concentration ranging from 25 to 1000 μg/mL. The cell medium in 96-
well plates was then replaced with the 100 μL of the fresh medium containing niosomes 
and incubated for 24 h. After the incubation, the ATP-based viability was measured by 
further adding 100 μL of reagent assay into each well (CellTiter-Glo Luminescent Cell 
Viability Assay, Promega, USA). The luminescence was measured with a Varioskan Flash 
plate reader (Thermo Fisher Scientific Inc., USA). The cells incubated with the cell culture 
medium and with Triton X-100 (1%) were measured as positive and negative controls, 
respectively. All the measurements were made triplicate. 
2.2.12 Cell uptake studies 
For qualitative evaluation of the cellular uptake of niosomes, 200 μL of MCF-7 and PC3-
MM2 cells were seeded into an 8-chamber slides (Nunc Lab-Tek II Chamber Slide System, 
Thermo scientific, Inc., USA) at a density of 2.5 × 104 cells per well, and incubated at 37°C 
overnight for proper attachment of the cells to the chamber. After the removal of the cell 
media, the cells were washed with HBSS-HEPES buffer (pH 7.4). Fluorescein 
isothiocyanate (FITC) labeled niosomes were prepared by loading the FITC during the 
aforementioned method for the preparation of drug loaded niosomes. 200 μL of FITC 
labelled niosome suspension with different concentrations were added in each chamber and 
incubated at 37°C for 6 h time. After incubation, the cells were washed thrice with HBSS-
HEPES buffer (pH 7.4) in order to remove the free niosomes and the cell membrane was 
stained with CellMask Deep Red (5 μL/mL, Invitrogen, USA) for 3 min at 37°C. Cells 
were again washed with HBSS-HEPES buffer (pH 7.4), washed and fixed with 4% 
paraformaldehyde (PFA) for 15 min, and washed with HBSS-HEPES buffer (pH 7.4). After 
the nuclei was stained by adding 200 μL of DAPI (4',6-diamidino-2-phenylindole, 2.8 
μL/mL, Thermo Scientific, USA) for 5 min, cells were washed again and stored with 200 
μL of HBSS-HEPES buffer (pH 7.4). The interaction of the niosomes with the cells was 
studied by a Leica SP5 inverted confocal microscope (Leica Microsystems, Germany), 
using a 63×1.2-0.6 oil immersion objective. 
2.2.13 Anti-proliferation assay  
The in vitro cell growth inhibition of the drug-loaded niosomes was evaluated against the 
MCF-7 and PC3-MM2 cancer cells by cell proliferation experiments. The anti-proliferation 
effects of free DOX, PXT, and drugs loaded niosomal formulations, containing different 
concentrations of drugs (25-500 µg/mL) were measured using the previously described 
protocol for the cytotoxicity studies. All the experiments were repeated three times.  
2.2.14 Statistical analysis 
The statistical significance was determined using Student’s t test (two-tailed); P < 0.05 was 
considered statistically significant in all the analyses (95% confidence level). 
 
3. Results and Discussion 
3.1 Preparation of niosomes 
Niosomes were prepared with constant amounts of Span 60, cholesterol and drug materials 
(DOX and/or PXT), but with varying amounts of Pluronic L121 and DCP. In the niosome 
structure, DOX as hydrophilic drug is encapsulated inside the vesicles and PXT as 
hydrophobic drug is entrapped into the bilayer structure. Cholesterol is situated in the 
bilayer structure rigidifying it and minimizing drug leakage, and making the drug release 
controlled. Three different levels of the amount of Pluronic L121 and DCP were studied. 
The central point composition for factorial design was selected to be 290 mg of Pluronic 
L121 and 1 mg of DCP. The exact compositions of all the niosome formulations are shown 
in Table 1. 
3.2 Size and surface properties of niosomes 
In this study, physicochemical parameters, size (<350 nm), PDI (<0.5) and zeta-potential 
(< -30 mV) were considered as critical quality attributes, CQAs, for the niosomes. The PDI 
value below 0.5 indicates low level of aggregation. Similarly, the zeta-potential value 
smaller than -30 mV means more stable niosomes with less aggregation tendency due to 
the electric repulsive forces (Mahale et al., 2012). DCP was added to the composition in 
order to reach lower zeta-potential values. Previous studies have shown that niosomal 
formulations containing cholesterol are rigid, stable and intact, while niosomes without 
cholesterol forms gel like systems, and for that reason cholesterol was added to all the 
compositions (Somjid et al., 2018).  
The non-ionic amphiphiles having hydrophilic-lipophilic balance (HLB) value greater than 
11, hinder the vesicular formation.  Span 60, selected for this study, forms rigid, stable and 
large in size niosomes having high drug entrapment efficiencies due to larger particle size 
(Basiri et al., 2017). Finally, the non-ionic polymeric surfactant, Pluronic L121, has the 
capability to entrap hydrophobic drugs, like PXT, efficiently inside the niosomes. And, it 
forms monodisperse and stable niosomes (Lee et al., 2005; Lee et al., 2011; Abdelbary and 
Tadros, 2013).  
The negative charge-imparting agent in this study was DCP. It gives for particle population 
low polydispersity values, due to strong inter-niosomal repulsive forces induced by the high 
surface charge (Helal et al., 2015). In this study, the size of all the niosomal formulations 
(with and without drug) were between 137 nm and 893 nm. The PDI ranged between 0.383 
and 0.725 and zeta-potential values were from -26.5 mV to -49.1 mV (Table 2).  Based on 
the size, size deviation and surface charge measurements, most of the studied niosomal 
formulations filled the above mentioned CQA requirements. 
  
Table 2. Particle sizes, PDI values, zeta-potentials, and drug entrapment efficiency values 
for studied niosomal formulations. 
Formulation Size (nm) PDI 
Zeta-potential 
(mV) %EE (DOX) %EE (PXT) 
D1 204.4 ± 8.7 0.470±0.069 -34.9± 0.5 92.90±0.13 - 
D2 182.9 ±  20.7 0.423±0.009 -36.8±1.6 93.49±0.20 - 
D3 241.1 ± 37.0 0.501±0.007 -34.3±2.6 92.32±0.18 - 
D4 202.1 ± 18.0 0.510±0.033 -46.9 ±1.1 92.99±0.20 - 
D5 190.1 ± 7.2 0.491±0.048 -39.6 ±1.1 92.73±0.20 - 
P1 195.3 ± 21.5 0.462±0.055 -35.9± 2.0 - 99.96±0.00 
P2 178.1 ± 3.0 0.417±0.027 -43.8± 0.6 - 99.98±0.00 
P3 169.3 ± 19.2 0.435±0.098 -49.1± 1.3 - 99.98±0.00 
P4 180.6 ± 7.2 0.447±0.076 -38.9±3.2 - 99.96±0.00 
P5 173.5 ± 42.6 0.383±0.025 -47.0± 1.3 - 99.97±0.00 
DP1 176.7 ± 11.4 0.493±0.010 -27.7±2.0 91.24±0.33 99.99±0.00 
DP2 156.6 ± 10.2 0.450±0.009 -26.5± 0.7 92.58±0.39 99.99±0.00 
DP3 147.6 ± 14.7 0.448±0.095 -32.1± 0.8 92.31±0.21 99.99±0.00 
DP4 168.2 ± 11.8 0.481±0.072 -39.0 ±2.4 92.39±0.13 99.99±0.00 
DP5 137.1 ± 4.1 0.437±0.046 -41.8±2.6 93.67±0.27 99.99±0.00 
E1 195.6 ± 12.8 0.492±0.047 -27.5 ± 0.9 - - 
E2 236.3 ± 36.0 0.391±0.105 -27.5 ± 0.9 - - 
E3 443.5 ± 86.7 0.469±0.037 -34.9 ± 3.4 - - 
E4 300.5 ± 36.6 0.448±0.034 -38.8 ± 0.3 - - 
E5 893.6 ± 135.5 0.725±0.117 -39.9 ± 5.2 - - 
 
Three batches failed to fulfill the PDI criteria, but two of these (D3 and D4) were very close 
to the critical value (0.501 and 0.510). D3 formulation did not contain DCP, and D4 
formulation contained the lowest amount of Pluronic L121 (246 mg). All the drug loaded 
niosomes were small in size, below 250 nm, but the size criteria was not fulfilled with two 
batches of empty niosomes E3 and E5 (E3 composition without DCP and E5 with the 
highest amount of Pluronic L121 (334 mg)). The zeta-potential value was not negative 
enough with four batches.  However, the zeta-potential of these four batches was from -
26.5 mV to -27.7 mV, which can still be considered high enough value to stabilize the 
niosomes. This was also confirmed in the stability studies, where all the batches showed 
good stability.    
3.3 Drug entrapment efficiency (%EE) 
The drug entrapment efficiency is very important property for drug formulations. In this 
study, the formulations that contained DOX, the %EE ranged between 92.32% and 93.49%. 
The formulations containing only PXT, the %EE was even higher, being between 99.96% 
to 99.98%. With the formulations containing both DOX and PXT, entrapment efficiencies 
for DOX varied between 91.24% and 93.67%, while PXT had in all the formulations 
99.99% entrapment efficiency value. Accordingly, the entrapment efficiencies were in very 
high level, especially entrapment of PXT was very close to 100%, and no real differences 
were seen in the entrapment efficiency values between different compositions with PXT.  
The high entrapment efficiency of PXT was due to its very low water solubility. The affinity 
of the drug inside the niosomes is very high due to its lipophilicity: it has very high tendency 
to escape from the outer aqueous phase to niosomes. Aqueous solubility of DOX is higher 
and it can partly be left into the aqueous phase, shown by the slightly lower entrapment 
efficiency values. However, the drug entrapment efficiency values were generally high for 
both the drugs in all the tested compositions, and it can be concluded that the compositions 
of niosome formulations have very minor effect on the entrapment efficiencies. 
In all the studied drug loaded formulations, the mean size of the niosomes was from 137 
nm to 241 nm. The composition is affecting the particle size of the niosomes, and particle 
size can also affect the entrapment efficiency: it is typical that larger particles are able to 
entrap the drugs more efficiently. However, in this study the changes in particle sizes were 
that small that any conclusions of its impact on the drug entrapment could not be 
withdrawn.  
Some examples of TEM images for niosomal formulations are shown in Figure 1. Based 
on the TEM analysis, the niosomes are close to spherical in shape and the sizes are 
corresponding well with the ones measured by DLS. No pure drug crystals were seen in 
TEM figures which is in accordance with the high drug entrapment values. This is also 
supported by the fact that the PDI values of the empty niosomes were in the same level or 
even higher than corresponding values for drug loaded niosomes. 
   
 
 
Figure 1. TEM images of E1 (figures A and B), and E2 (figures C and D) compositions of 
niosome formulations. 
 
3.4 Stability studies 
For stability testing purposes, all the niosomes were stored at 4°C for 4 weeks, and all the 
formulations were studied taking into account the above-mentioned CQAs as critical 
stability parameters. The niosomes (without drug) tend to increase in the size, but after one 
week in storage, they became stable. It is typical that after the process stress (here 
sonication), particle size can change a little bit before reaching a constant value. This is due 
to the relaxation process after the stress (sonication) phase is over. The particle sizes of the 
empty niosomes ranged between 195 nm and 893 nm with PDI values from 0.39 to 0.72, 
and zeta-potentials ranging from -27 mV to -39 mV as shown in Table 3. During the whole 
storage time (4 weeks), all the drug-loaded niosomes were stable and only a little 
fluctuation in size was seen. Most stable formulations were the center point formulations 
D1, P1 and DP1 as well as formulations containing 2 mg of DCP, e.g. D2, P2 and DP2. 
The zeta-potential of the formulations D1, D2, P1, P2, DP1 and DP2 were deviating from 
the predetermined CQAs and was close to the limiting values. However, the low PDI values 
and stable particle sizes suggested a low level of aggregation and high stability of the 
niosomes, demonstrating good quality of these batches, too. The niosomes remained stable 
with low PDI values during the stability testing time as indicated in Table 3. The results 
indicated that higher quantities of DCP (1 or 2 mg) and medium quantity of Pluronic L121 
(290 mg) showed the best stability of niosomes. 
Table 3. Particle size, PDI and zeta-potential values of fresh (just after the production) and stored (at 4°C) niosomal formulations. 
 
Time  Parameters E1 E2 E3 E4 E5 D1 D2 D3 D4 D5 
F
r
e
sh
 
sa
m
p
le
s Size (nm) 195.6±12.8 236.3±36.0 443.5±86.7 300.5±36.6 893.6±135.5 204.4±8.7 182.9±20.7 241.1±37.0 202.1±18.0 190.1±7.2 
PDI 0.492±0.047 0.391±0.105 0.469±0.037 0.448±0.034 0.725±0.117 0.470±0.069 0.423±0.009 0.501±0.007 0.510±0.033 0.491±0.048 
Zeta-potential (mV) -27.5 ±0.9 -27.5± 0.9 -34.9± 3.4 -38.8±0.3 -39.9±5.2 - 34.9± 0.5 -36.8±1.6 - 34.3±2.6 - 46.9. ±1.1 - 39.6±1.1 
1
 w
e
e
k
 Size (nm) 223.4±11.4 175.8±5.8 294.4±8.0 199.3±5.4 244.8±7.6 200.0±7.0 185.2±10.1 240.1±36.2 200.2±10.2 192.1±9.1 
PDI 0.340±0.046 0.198±0.040 0.362±0.038 0.282±0.014 0.535±0.020 0.341±0.011 0.314±0.071 0.430±0.017 0.490±0.033 0.451±0.011 
Zeta-potential (mV)   - 23.8±0.9 - 26.9± 0.9 - 28.2± 1.0 - 28.5 ±0.6 - 30.4±0.5 - 32.3± 0.1 - 34.0±1.5 - 34.1±2.2 - 46.1. ±2.2 - 36.8±2.1 
2
 w
e
e
k
s Size (nm) 191.9±3.3 178.7±3.6 347.4±9.0 212.7±6.1 245.2±5.5 201.0±4.0 183.5±9.1 241.3±20.2 207.6±12.2 193.1±5.2 
PDI 0.168±0.039 0.169±0.028 0.375±0.030 0.299±0.022 0.543±0.015 0.340±0.019 0.310±0.011 0.415±0.011 0.450±0.011 0.410±0.034 
Zeta-potential (mV) - 23.8±0.9 - 28.1± 2.2 - 29.5±2.5 - 28.2 ±3.0 - 26.3±0.5 - 32.5± 0.1 - 33.9±1.6 - 33.5±3.3 - 45.0 ±3.1 - 36.2±3.1 
3
 w
e
e
k
s Size (nm) 199.4±4.9 172.2±1.7 296.3±12.6 208.7±4.6 291.6±8.3 203.1±2.6 182.9±11.2 253.6±26.4 215.2±12.2 201.3±5.1 
PDI 0.213±0.011 0.151±0.033 0.320±0.051 0.324±0.020 0.532±0.051 0.331±0.054 0.315±0.039 0.420±0.027 0.450±0.011 0.421±0.091 
Zeta-potential (mV) - 27.2 ±0.4 - 28.9± 0.5 - 28.6±1.5 - 31.6 ±2.2 - 28.9±0.2 - 32.7± 0.1 - 33.5±3.2 - 34.0±3.3 - 45.1. ±2.1 - 36.2±7.1 
4
 w
e
e
k
s Size (nm) 186.8±1.6 182.0±2.7 311.8±8.1 190.0±2.5 255.8±34.8 201.2±4.0 183.5±9.1 260.6±26.4 221.2±12.2 210.3±5.1 
PDI 0.138±0.025 0.226±0.016 0.364±0.042 0.208±0.037 0.534±0.078 0.340±0.019 0.310±0.011 0.420±0.027 0.450±0.011 0.421±0.091 
Zeta-potential (mV)  - 25.5 ±1.3 - 27.3± 1.5 - 26.7±0.2 - 27.8 ±1.0 - 29.8±1.1 - 32.5± 0.1 - 33.2±1.7 - 34.0±3.3 - 45.1±2.1 - 36.2±7.1 
  
  P1 P2 P3 P4 P5 DP1 DP2 DP3 DP4 DP5 
F
r
e
sh
 
sa
m
p
le
s Size (nm) 195.3±21.5 178.1±3.0 169.3±19.2 180.6±7.2 173.5±42.6 176.7±11.4 156.6±10.2 147.6±14.7 168.2±12.0 137.1±4.1 
PDI 0.462±0.055 0.417±0.027 0.435±0.098 0.447±0.076 0.383±0.025 0.493±0.010 0.450±0.009 0.448±0.095 0.481±0.072 0.437±0.046 
Zeta-potential (mV)  - 35.9± 2.0 - 43.8± 0.6 - 49.1± 1.3 - 38.9±3.2 - 47.0± 1.4 - 27.7±2.0 - 26.5± 0.8 - 32.1± 1.0 - 39.0 ±2.4 - 41.8±2.7 
1
 w
e
e
k
 Size (nm) 193.2±11.1 175.2±5.6 165.3±12.1 181.5±5.2 170.5±22.7 171.7±10.1 157.2±10.3 146.3±11.6 167.5±12.8 141.1±4.1 
PDI 0.342±0.029 0.317±0.011 0.397±0.018 0.417±0.016 0.313±0.011 0.393±0.032 0.390±0.019 0.380±0.095 0.430±0.011 0.430±0.146 
Zeta-potential (mV)  - 32.2± 3.0 - 39.1± 0.6 - 45.1± 7.3 - 35.3±1.2 - 45.0± 1.3 - 27.5±1.4 - 25.5± 0.4 - 31.2± 0.6 - 35.1 ±2.1 - 39.2±5.7 
2
 w
e
e
k
s Size (nm) 195.0±10.2 172.3±5.2 170.3±22.2 186.5±10.1 175.9±12.2 170.7±10.2 155.0±10.4 149.4±15.2 168.9±21.1 144.6±7.2 
PDI 0.331±0.039 0.310±0.011 0.410±1.018 0.419±0.026 0.321±0.021 0.389±0.011 0.379±0.013 0.389±0.011 0.410±0.025 0.429±0.210 
Zeta-potential (mV) - 32.0± 3.7 - 39.28± 0.2 - 45.1± 4.3 - 35.6±2.1 - 43.6± 1.5 - 27.2±1.1 - 26.1± 2.0 - 31.2± 0.1 - 35.9 ±2.2 - 39.5±3.5 
3
 w
e
e
k
s Size (nm) 191.1±10.2 175.9±5.1 198.3±22.2 195.5±8.2 189.9±10.2 172.3±15.1 154.3±10.2 170.2±10.4 192.3±19.3 177.2±7.1 
PDI 0.310±0.039 0.335±0.011 0.397±1.018 0.410±0.026 0.325±0.021 0.390±0.012 0.389±0.313 0.391±0.321 0.419±0.011 0.437±0.217 
Zeta-potential (mV)  - 32.9± 4.0 - 39.3± 0.5 - 45.6± 4.3 - 35.2±2.3 - 44.9± 1.4 - 27.9±3.1 - 26.5± 3.4 - 31.4± 1.2 - 35.5 ±2.3 - 39.3±4.2 
4
 w
e
e
k
s Size (nm) 194.0±10.1 176.4±5.3 207.3±22.1 210.5±8.1 197.9±10.2 171.7±15.1 156.4±9.6 183.4±15.1 212.4±21.1 191.6±7.3 
PDI 0.350±0.039 0.310±0.011 0.381±1.018 0.410±0.026 0.327±0.021 0.370±0.012 0.376±0.213 0.389±0.011 0.431±0.025 0.423±0.210 
Zeta-potential (mV)  - 32.3± 4.2 - 39.3± 0.6 - 45.9± 4.2 - 35.2±2.2 - 43.5±1.4 - 27.4±3.1 - 26.9± 2.1 - 31.2± 0.2 - 35.2 ±2.3 - 39.7±3.6 
3.5 Interaction studies   
3.5.1 ATR-FTIR spectroscopy 
The ATR-FTIR spectroscopy is a pre-formulation study for the evaluation of compatibility 
between the formulation ingredients. The ATR-FTIR spectra of DOX, PXT, and all the other 
ingredients individually, the physical mixtures of formulations, and their corresponding 
niosomal formulations are shown in Figure 2.  
 
Figure 2. ATR-FTIR spectra of different raw materials, physical mixtures and niosomal 
formulations. 
The pure DOX showed peaks at 3456 cm-1 and 3335 cm-1 due to the N-H stretching of 
primary amine and O-H stretching, respectively. The peaks at 868 cm-1 and 807 cm-1 were 
seen due to N-H group stretching (Majeed et al., 2013). The ATR-FTIR spectrum of PXT 
(pure drug) showed peaks between 3479 cm-1to 3300 cm-1 due to the stretching of N-H, CH2 
stretching peaks between 2976-2885 cm-1, C=O stretching at 1734 cm-1, the amide bond 
stretching at 1647 cm-1, ester bond and C-N stretching at 1254 cm-1 and 1276 cm-1, 
respectively, and peaks due to aromatic bonds were seen at 1647, 1074, 963 and 709 cm-1 
(Martins et al., 2014). Span 60 gave peaks at 2916.75 cm-1 due to (-OH stretch, broad), 
2849.58 cm-1 (-OH stretch, broad), a 5-membered cyclic ring peak at 1734.65 cm-1 and small 
peaks due to aliphatic groups from 1000-1200 cm-1 (Li et al., 2008) Pluronic L121 showed 
peak stretch at 2990 cm-1 of asymmetrical methyl (C-H), scissoring of C-H bondage at 1480 
cm-1 , symmetrical C-H bond at 1387 cm-1 and ether linkage (C-O-C) at 1120 cm-1 (Newman 
et al., 1998).  Cholesterol showed ATR-FTIR peaks at 2931.41 cm-1 of acetyl group, 2866.83 
cm-1 symmetric -CH3, at 1770.20 cm
-1 and 1055.17 cm-1 due to vinyl group and R-O groups, 
respectively (Khan et al., 2015).  
The ATR-FTIR of the physical mixtures of the optimized formulations and their relevant 
niosomal formulations were also studied. The spectra of both the physical mixtures and the 
niosomal formulations were similar and diffusion of the peaks were seen without peak 
shifting. Similar interactions between the ingredients was seen as in the earlier studies, 
where it was suggested that there was interactions between the Span 60 and cholesterol to 
give rigid and stable structure for niosomes (Nasseri, 2005). The found interaction is 
between the glycerol oxygen in Span molecule and β-OH group in cholesterol molecule; 
changes due to this interaction were seen in the spectrograms.  
3.5.2 Thermal analysis 
In the thermal analysis of Span 60, DCP, cholesterol, DOX and PXT, they showed 
endothermic characteristic melting peaks at 54°C, 78°C, 150°C, 205°C and 220°C, 
respectively (Figure 3). The physical mixtures of formulations (D1, P1 and DP1) showed 
the slightly broader peaks at 38°C and 57°C which indicates the interaction between the 
Span 60 and cholesterol (Nasseri, 2005), as already mentioned related to the discussion of 
ATR-FTIR results, and which was also seen with the niosomal formulations D1, P1 and 
DP1. Also, a slightly broader peak was seen at 140 °C due to cholesterol. The peaks of 
membrane formers indicated mutual interactions, which resulted in more stable niosomes as 
indicated by the stability studies data and also by the entrapment efficiency values. The 
slightly broader peaks of drugs were seen in the range of 205°C to 230°C which indicated 
that the drugs were in their crystalline form as have been indicated in previous studies 
(Pawar and Vavia, 2016; Doustgani, 2017).  
 
 
Figure 3. DSC thermograms of pure materials, physical mixtures and niosome formulations 
with PAX (P), DOX (D) and DOX and PAX (DP). 
3.6 Drug Release Studies 
The in vitro drug release testing from the niosomes was performed in HBSS-HEPES (pH 
7.4) with 4% Tween 80 addition (Yang et al., 2007a; Figueiredo et al., 2017). The release 
profiles of DOX and PXT are summarized in Figure 4. From pure DOX powder, the 
dissolution was very fast. Drug release from the DOX niosomes was biphasic in nature: in 
the first phase, burst type of release was seen, which was followed by a constant sustained 
release phase. Dissolution rate from DOX niosomes was a little bit slower as compared to 
pure drug: from niosome formulations containing only DOX, drug release after 24 h time 
was approximately 93%. Also, with the formulations containing both DOX and PXT, same 
kind of burst release was seen, but it was comparatively in lower level as compared to the 
formulations containing only DOX. Later, a constant sustained release of DOX from DOX 
and PXT loaded niosomes was observed reaching approximately 40% level within 24 h. 
Also with PXT, the biphasic release was observed. In the first phase, burst type release was 
seen and later a constant sustained release of PXT was seen from formulations containing 
only PXT reaching the approximated level of 26% within 24 h. Again, with the 
formulations containing both DOX and PXT, a burst release of PXT was seen, but similarly 
to DOX release, it was less as compared to the formulations containing only PXT. In the 
second phase, a constant sustained release of PXT was observed reaching the approximated 
level of 18% within 24 h. All the PXT loaded niosomes showed much higher dissolution 
rates as compared to pure PXT. 
The niosomal formulations containing both DOX and PXT showed lower drug release rates 
as compared with the formulations containing only one drug.    
  
Figure 4. Drug release from formulations containing A) DOX, B) PXT, and formulations 
containing DOX and PXT, release of C) DOX, and D) PXT.  
3.7 Cell viability assay 
The biocompatibility of the niosomes is an important criterion for their application as a 
drug delivery system. In this study, the cytotoxicity of the niosomes was evaluated against 
MCF-7 and PC3-MM2 cell lines by incubating them for 24 h using different niosome 
concentrations as shown in Figure 5. With empty niosomes, weak concentration related 
effect on viability was noticed as compared to the negative control, but  the viability of the 
cells with even the highest tested niosome concentration, 1 000 µg/ml of niosomes, was not 
significantly lowered  with either MCF-7 or PC3-MM2 cell lines (with both cell lines 
p>0.05). With all the studied concentrations, the viability values were higher with MCF-7 
cells as compared to PC3-MM2 cells.  
  
Figure 5. Cell viability assay of niosomal formulations against MCF-7 and PC3-MM2 
cells after  24 h incubation. 
3.8 Cell uptake studies 
The cell uptake efficiency of the anticancer drug loaded niosomes is an important factor for 
the estimation of potency of drug formulations. A fluorescent compound, FITC, was 
incorporated into the niosomes, cell membranes were stained with CellMask Deep Red and 
nuclei with DAPI. The confocal images (Figure 6) of MCF-7 and PC3-MM2 cell lines were 
examined by incubating them at 37°C for 6 h. Based on the confocal images, the niosomes 
were taken up by the cells and they were accumulated into the cytoplasm of the cells 
successfully. In earlier studies, it has been shown that the internalization of niosomes can 
be facilitated by the presence of lipid content of niosomes and its interaction with the lipid 
membrane of the cells (Guo et al., 2015; Shi et al., 2015; Tahir et al., 2017). The size of 
the niosomes also affects internalization and drug delivery into the cells. In the present 
study, the smallest size fractions (<200 nm) of niosomes had better penetration due to 
having small size, and the larger niosomes had less penetration capacity, which has also 
been described in previous studies (Shahbazi et al., 2014; Khutale and Casey, 2017). The 
formulation E2 showed the best internalization of the niosomes when compared with other 
formulations. In other formulations, part of the niosomes remained outside of the cells and 
adhered to cell surfaces.   
  
 Figure 6. Confocal images of niosomal formulations uptake by MCF-7 and PC3-MM2 cells.
3.9 Antiproliferative studies 
The antiproliferative activity of the anticancer drugs (DOX, PXT) loaded niosomes was 
measured by ATP activity based luminescence assay as indicated in Figure 7. The effect of pure 
drugs, empty niosomes, and niosomes containing the anticancer drugs, was evaluated on MCF-
7 and PC3-MM2 cell lines. The effect of the pure drugs was seen to be concentration dependent. 
DOX showed more antiproliferative effect on PC3-MM2 cells as compared to PXT pure drug at 
highest concentration levels (500 µg/ml, P<0.05), but in MCF-7 cell line there were no statistical 
difference in antiproliferative effect between the pure drugs in the highest concentration. The 
niosomal formulations showed time and concentration dependent type of activity.  
In MCF-7 cell line the formulations containing both drugs didn’t differed from formulations 
having either of the drug alone. But, In PC3-MM2 cells, dual drug therapy (DOX+PTX 
niosomes) showed better antiproliferative effect on cancerous cell lines and efficacy of the 
niosomal formulations as compared to either DOX alone (P<0.01) or PTX alone (P<0.05). The 
formulations containing paclitaxel and doxorubicin (DP1-DP5) showed improvement of 
antiproliferation against MCF-7 and PC3-MM2 cells. The efficacy against PC3-MM2 is much 
higher than MCF-7 (P<0.01). It showed concentration and time dependent activity.   
The in-vitro release studies showed the sustained drug release behavior of the formulations, 
which is also clear from the cell line antiproliferation studies. The increase in incubation time of 
cells would improve the effects. But, the results were in line with the results of release studies of 
the formulations, which was sustained drug release which is also reported in previous findings 
(Tahir et al., 2017; Alemi et al., 2018). 
 
 Figure 7. Antiproliferative study of different concentrations of drugs on MCF-7 and PC3-MM2 cell 
after 24 h incubation time. 
 
 
Conclusion 
In the present study, two cytotoxic drugs, doxorubicin and paclitaxel, were encapsulated into 
niosome formulations by using an ecofriendly probe sonication method. The niosomes prepared 
with fixed amount of Span 60 and cholesterol, and with varying amount of Pluronic L121 and 
dicetylphosphate showed high entrapment efficiencies, as well as acceptable size and 
monodispersity levels. In-vitro characterization showed that the formulations had sustained drug 
release profiles, low toxicity even at high concentrations, better cell penetration and improved 
antiproliferative effects in time and dose dependent manner. Further, niosomes showed 
synergistic effect due to the presence of two anticancer drugs.   
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